Gene-Cloned Entomopathogenic Fungi Formulation for Sustainable Bagworm Pest Control

Overview

This research addresses the urgent need for sustainable pest management in agriculture by developing a biological control formulation based on Isaria fumosorosea, a naturally occurring entomopathogenic fungus. The solution targets bagworm pests, which are destructive lepidopteran insects that threaten oil palm and other crops. Field validation studies have already demonstrated that I. fumosorosea formulations can suppress bagworm populations below the economic threshold level within 45 days of application, with effects lasting up to 60 days. The product offers a compelling alternative to broad-spectrum chemical insecticides, providing effective pest suppression while remaining safe for pollinators, humans, and the broader environment.

Technical specifications

Key features:

• Based on Isaria fumosorosea, a cosmopolitan entomopathogenic fungus with proven efficacy against multiple insect species
• Utilizes chitinase enzymes produced by the fungus to degrade insect cuticles and initiate infection
• Demonstrated ability to reduce bagworm (Metisa plana) populations below the economic threshold of 10 larvae per frond
• Effective pest suppression lasting up to two months in field conditions
• Safe for non-target organisms including pollinators and humans
• Planned gene cloning approach to transfer specific virulence-related genes into alternative host organisms for easier and more cost-effective mass production

Applications:

• Oil palm plantations facing bagworm infestations
• Other agricultural crops affected by lepidopteran pests
• Integrated pest management programs seeking to reduce chemical pesticide dependency

Technology readiness level

The formulation has completed initial field validation, demonstrating significant population reductions of bagworm pests in crop environments. The current TRL reflects successful proof-of-concept and preliminary efficacy data from field trials. The next phase involves gene cloning to enhance production scalability, with planned work in bioreactor-based mass production and formulation development. Additional field trials are required to generate robust data sets for commercial adoption. The project timeline is approximately one year for the gene cloning and production scale-up phase, with ongoing field validation to build the evidence base needed for market entry and customer confidence.